• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Insurance status affects treatment of early stage breast cancer

bys25qthea
April 27, 2013
in Chronic Disease, Obstetrics, Oncology, Public Health
Reading Time: 3 mins read
USPSTF recommends chemoprevention for women at high risk for breast cancer
Share on FacebookShare on Twitter

Image: PD

1.  Women with Medicaid on average presented with significantly larger tumors and on the whole were more likely to be treated with mastectomy than women with private insurance. 

2. Women with private insurance were more likely than women with Medicaid to receive a mastectomy for smaller tumors. 

Evidence Rating Level: 2 (Good) 

Study Rundown: This study is one of the first to look at the effects of insurance type (Medicaid vs. private insurance) on the treatment of breast cancer. Researchers found that although women on Medicaid were more likely to present with larger tumors and thus were more likely to receive mastectomy, women with private insurance were more likely to receive mastectomy for smaller tumors, in which breast conserving therapies (i.e. lumpectomy) have been shown to provide equivalent survival rates while being more cost effective.

Although the study asks a novel question, results are limited in generalizability because the study cohort was taken from one health system. Further studies should be repeated in different populations. Moreover, they should look into not only why women with Medicaid are presenting at later stages, but also why women with private insurance are receiving mastectomies for smaller tumors when the evidence states that less invasive procedures are indicated.

RELATED REPORTS

Cognitive behaviour therapy may be superior to bright light therapy for insomnia in women with breast cancer undergoing chemotherapy

Tumour microenvironment factors may influence cancer progression and response to tamoxifen (Nolvadex) in patients with estrogen receptor-positive and human epidermal growth factor receptor 2 breast cancer

2 Minute Medicine Rewind August 10, 2026

Click to read the study in JAMA Surgery

In-Depth [retrospective analysis]: included women with stage I-III invasive breast cancer who had surgery from 1996-2009 in the ProMedica Health System in Toledo, Ohio. The primary outcome examined was rates of mastectomy between Medicaid and private insurance. Additionally, logistic regression analyses were done to assess the association between various variables (age, size and stage of tumor at diagnosis) and use of mastectomy.

Of the 1,539 women included in the study 651 (42%) were treated with mastectomy compared with 888 (58%) treated with breast conserving therapy (BCT). Women with Medicaid were more likely to present with significantly larger tumors at diagnosis than those with private insurance (3.3 cm vs 2.1 cm, p<0.05) and received significantly more mastectomies on the whole (60% vs 39%, p<0.05). Of women with smaller tumors (<2 cm), those on Medicaid were less likely than women with private insurance to receive full mastectomy (11% vs 47%, p<0.05).

By Maren Shapiro and Leah Hawkins

More from this author: Black men less likely to receive follow-up for elevated prostate cancer marker, PSA,  More U.S. women using emergency contraception pill, No-cost contraception reduces unintended pregnancies 

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain. 

Tags: Breast Cancer
Previous Post

Coronary bypass survival benefits shine in high-risk patients

Next Post

Integrated 2D/3D mammography improves breast cancer detection

RelatedReports

Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation
Chronic Disease

Cognitive behaviour therapy may be superior to bright light therapy for insomnia in women with breast cancer undergoing chemotherapy

September 3, 2026
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Chronic Disease

Tumour microenvironment factors may influence cancer progression and response to tamoxifen (Nolvadex) in patients with estrogen receptor-positive and human epidermal growth factor receptor 2 breast cancer

August 13, 2026
Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation
Weekly Rewinds

2 Minute Medicine Rewind August 10, 2026

August 10, 2026
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Chronic Disease

A digital mental health intervention may improve anxiety in breast cancer survivors

July 31, 2026
Next Post
One third of breast cancer survivors report pain 5-7 years after treatment

Integrated 2D/3D mammography improves breast cancer detection

The PROVE IT trial: High-dose statin regimen reduces mortality after ACS [Classics Series]

Chromosomal analysis not cost-effective in evaluation of recurrent miscarriage

Chromosomal analysis not cost-effective in evaluation of recurrent miscarriage

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Earlier Genetic Testing Predicts Bilateral Mastectomy in Young BRCA Carriers
  • Uterine-Sparing Mesh Repair Outperforms Hysterectomy for Prolapse
  • Daraxonrasib showed antitumor activity in previously treated RAS-mutant non–small-cell lung cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.

2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in